{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:55:16Z","timestamp":1790740516283,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Southampton National Institute for Health Research Biomedical Research"},{"name":"Parnell Diabetes Trust"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.mam.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T10:29:54Z","timestamp":1521714594000},"page":"135-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"special_numbering":"C","title":["Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7547-146X","authenticated-orcid":false,"given":"Eleonora","family":"Scorletti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1194\/jlr.P032276","article-title":"Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement","volume":"54","author":"Al-Hilal","year":"2013","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3945\/ajcn.116.131896","article-title":"A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the comparing EPA to DHA (ComparED) study","volume":"104","author":"Allaire","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12263-013-0362-6","article-title":"ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement","volume":"9","author":"Alsaleh","year":"2014","journal-title":"Genes & nutrition"},{"issue":"16","key":"10.1016\/j.mam.2018.03.001_bib4","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib5","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2014.08.036","article-title":"Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial","volume":"62","author":"Argo","year":"2015","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.269","article-title":"Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts","volume":"41","author":"Aulchenko","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mam.2018.03.001_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.plipres.2016.07.002","article-title":"Metabolism and functional effects of plant-derived omega-3 fatty acids in humans","volume":"64","author":"Baker","year":"2016","journal-title":"Prog. Lipid Res."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib10","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.22009","article-title":"Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach","volume":"47","author":"Bellentani","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1194\/jlr.M500365-JLR200","article-title":"Docosahexaneoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways","volume":"47","author":"Botolin","year":"2006","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4274\/jcrpe.1749","article-title":"Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease","volume":"7","author":"Boyraz","year":"2015","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.20920","article-title":"Insulin resistance: a metabolic pathway to chronic liver disease","volume":"42","author":"Bugianesi","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1079\/NRR2005113","article-title":"Dietary alpha-linolenic acid and health-related outcomes: a metabolic perspective","volume":"19","author":"Burdge","year":"2006","journal-title":"Nutr. Res. Rev."},{"issue":"8","key":"10.1016\/j.mam.2018.03.001_bib15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"4\u20136","key":"10.1016\/j.mam.2018.03.001_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.plefa.2010.02.012","article-title":"Fatty liver: role of inflammation and fatty acid nutrition","volume":"82","author":"Byrne","year":"2010","journal-title":"Prostagl. Leukot. Essent. Fat. Acids"},{"issue":"Pt 1","key":"10.1016\/j.mam.2018.03.001_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/bj2880101","article-title":"Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin","volume":"288","author":"Byrne","year":"1992","journal-title":"Biochem. J."},{"issue":"1 Suppl. l","key":"10.1016\/j.mam.2018.03.001_bib18","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"issue":"6 Suppl. l","key":"10.1016\/j.mam.2018.03.001_bib19","article-title":"n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases","volume":"83","author":"Calder","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.mam.2018.03.001_bib20","first-page":"1","article-title":"Very long-chain n-3 fatty acids and human health: fact, fiction and the future","author":"Calder","year":"2017","journal-title":"Proc. Nutr. Soc."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3810\/pgm.2009.11.2083","article-title":"Understanding omega-3 polyunsaturated fatty acids","volume":"121","author":"Calder","year":"2009","journal-title":"PGM (Postgrad. Med.)"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3350\/cmh.2017.0103","article-title":"NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs","volume":"23","author":"Caldwell","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050774","article-title":"The natural course of non-alcoholic fatty liver disease","volume":"17","author":"Calzadilla Bertot","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.mam.2018.03.001_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.mam.2018.03.001_bib25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1365-2036.2006.02885.x","article-title":"Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study","volume":"23","author":"Capanni","year":"2006","journal-title":"Aliment Pharmacol. Therapeut."},{"issue":"7","key":"10.1016\/j.mam.2018.03.001_bib26","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mam.2018.03.001_bib27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10620-012-2489-5","article-title":"Fish Omega-3 fatty acids induce liver fibrosis in the treatment of bile duct-ligated rats","volume":"58","author":"Chih-Cheng Chen","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0168-8278(03)00191-0","article-title":"Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease","volume":"39","author":"Colloredo","year":"2003","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s12263-014-0437-z","article-title":"Effects of FADS and ELOVL polymorphisms on indexes of desaturase and elongase activities: results from a pre-post fish oil supplementation","volume":"9","author":"Cormier","year":"2014","journal-title":"Genes & nutrition"},{"issue":"12","key":"10.1016\/j.mam.2018.03.001_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122645","article-title":"Impact of Omega-3 fatty acids on the gut microbiota","volume":"18","author":"Costantini","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.mam.2018.03.001_bib31","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/jc.2009-0870","article-title":"Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy","volume":"94","author":"Cussons","year":"2009","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","article-title":"Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis","volume":"49","author":"Dasarathy","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","author":"EASL-EASD-EASO","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"10.1016\/j.mam.2018.03.001_bib34","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.jhep.2008.01.009","article-title":"Non-alcoholic fatty liver disease: the mist gradually clears","volume":"48","author":"de Alwis","year":"2008","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clnu.2017.01.006","article-title":"Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids","volume":"37","author":"de Castro","year":"2018","journal-title":"Clin. Nutr."},{"issue":"12","key":"10.1016\/j.mam.2018.03.001_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168216","article-title":"Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: results from a single centre trial","volume":"11","author":"Della Corte","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3945\/jn.112.171322","article-title":"Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-\/-) mouse model of western diet-induced nonalcoholic steatohepatitis","volume":"143","author":"Depner","year":"2013","journal-title":"J. Nutr."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.atherosclerosis.2008.12.019","article-title":"Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role?","volume":"205","author":"Dietrich","year":"2009","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib39","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic Review and Meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000360511","article-title":"Treatment of non-alcoholic fatty liver disease","volume":"32","author":"Dyson","year":"2014","journal-title":"Dig. Dis."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-0030-1267539","article-title":"Novel insights into the pathophysiology of nonalcoholic fatty liver disease","volume":"30","author":"Feldstein","year":"2010","journal-title":"Semin. Liver Dis."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib42","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of >\/= 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13105-016-0495-3","article-title":"Dietary long-chain unsaturated fatty acids acutely and differently reduce the activities of lipogenic enzymes and of citrate Carrier in rat liver","volume":"72","author":"Gnoni","year":"2016","journal-title":"J. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib44","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ypmed.2004.02.030","article-title":"The Omega-3 Index: a new risk factor for death from coronary heart disease?","volume":"39","author":"Harris","year":"2004","journal-title":"Prev. Med."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib45","first-page":"131","article-title":"Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia","volume":"23","author":"Hatzitolios","year":"2004","journal-title":"Indian J. Gastroenterol. : official journal of the Indian Society of Gastroenterology"},{"issue":"10","key":"10.1016\/j.mam.2018.03.001_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162368","article-title":"Effectiveness of Omega-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"He","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.mam.2018.03.001_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2013.07.001","article-title":"Role of the intestinal microbiome in liver disease","volume":"46","author":"Henao-Mejia","year":"2013","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.mam.2018.03.001_bib48","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MPG.0b013e31822578db","article-title":"Mechanisms of lipotoxicity in NAFLD and clinical implications","volume":"53","author":"Ibrahim","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.5876","article-title":"Relationships between plasma fatty acid composition and coronary artery disease","volume":"18","author":"Itakura","year":"2011","journal-title":"J. Atherosclerosis Thromb."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib51","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jpeds.2015.01.056","article-title":"Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial","volume":"166","author":"Janczyk","year":"2015","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib52","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3945\/an.115.009423","article-title":"Potential for dietary omega-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer","volume":"6","author":"Jump","year":"2015","journal-title":"Advances in nutrition (Bethesda, Md)"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S002966511500244X","article-title":"Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-\/- mice","volume":"75","author":"Jump","year":"2016","journal-title":"Proc. Nutr. Soc."},{"key":"10.1016\/j.mam.2018.03.001_bib54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pharmthera.2017.07.007","article-title":"Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease","volume":"181","author":"Jump","year":"2018","journal-title":"Pharmacol. Therapeut."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3945\/an.111.000505","article-title":"(n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights","volume":"2","author":"Kalupahana","year":"2011","journal-title":"Advances in nutrition (Bethesda, Md)"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng.291","article-title":"Common variants at 30 loci contribute to polygenic dyslipidemia","volume":"41","author":"Kathiresan","year":"2009","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.mam.2018.03.001_bib57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/met.2016.0051","article-title":"Treatment of nonalcoholic fatty liver disease with long-chain n-3 polyunsaturated fatty acids in humans","volume":"14","author":"Kelley","year":"2016","journal-title":"Metab. Syndrome Relat. Disord."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib58","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1053\/j.gastro.2015.09.015","article-title":"Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists","volume":"149","author":"Kleiner","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/01.ATV.0000057393.97337.AE","article-title":"Omega-3 fatty acids and cardiovascular disease: new recommendations from the American heart association","volume":"23","author":"Kris-Etherton","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib60","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clnu.2009.11.005","article-title":"Do FADS genotypes enhance our knowledge about fatty acid related phenotypes?","volume":"29","author":"Lattka","year":"2010","journal-title":"Clin. Nutr. (Edinb.)"},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1079\/BJN2002556","article-title":"Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses","volume":"87","author":"Leigh-Firbank","year":"2002","journal-title":"Br. J. Nutr."},{"issue":"7","key":"10.1016\/j.mam.2018.03.001_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002193","article-title":"Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium","volume":"7","author":"Lemaitre","year":"2011","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0163-7827(03)00040-7","article-title":"Elongation of long-chain fatty acids","volume":"43","author":"Leonard","year":"2004","journal-title":"Prog. Lipid Res."},{"issue":"7","key":"10.1016\/j.mam.2018.03.001_bib65","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2559.2011.04145.x","article-title":"The epidemiology, pathogenesis and histopathology of fatty liver disease","volume":"61","author":"Levene","year":"2012","journal-title":"Histopathology"},{"issue":"22","key":"10.1016\/j.mam.2018.03.001_bib67","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.3748\/wjg.v21.i22.7008","article-title":"Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis","volume":"21","author":"Li","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib68","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.mam.2018.03.001_bib69","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1194\/jlr.M061275","article-title":"Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-\/- mice by targeting the TGFbeta-Smad3 pathway","volume":"56","author":"Lytle","year":"2015","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib70","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mrm.20825","article-title":"Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy","volume":"55","author":"Machann","year":"2006","journal-title":"Magn. Reson. Med."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11745-008-3158-5","article-title":"SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease","volume":"43","author":"Malerba","year":"2008","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib72","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1440-1746.2010.06326.x","article-title":"Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model","volume":"26","author":"Marsman","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.atherosclerosis.2004.04.004","article-title":"Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein","volume":"175","author":"Mesa","year":"2004","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.mam.2018.03.001_bib74","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.nut.2011.11.031","article-title":"Association between interaction and ratio of omega-3 and omega-6 polyunsaturated fatty acid and the metabolic syndrome in adults","volume":"28","author":"Mirmiran","year":"2012","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib75","first-page":"95","article-title":"The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans","volume":"9","author":"Mori","year":"2006","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib76","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/ajcn\/71.5.1085","article-title":"Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men","volume":"71","author":"Mori","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"issue":"12","key":"10.1016\/j.mam.2018.03.001_bib77","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1345\/aph.1K286","article-title":"Effects of thiazolidinediones on bone loss and fracture","volume":"41","author":"Murphy","year":"2007","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib78","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/jhep.2003.50132","article-title":"Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis","volume":"37","author":"Musso","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib79","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.23623","article-title":"A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso","year":"2010","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.mam.2018.03.001_bib80","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/hepr.12887","article-title":"Ezetimibe for the treatment of non-alcoholic fatty liver disease: a meta-analysis","volume":"47","author":"Nakade","year":"2017","journal-title":"Hepatol. Res."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib81","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00439-010-0815-6","article-title":"A single nucleotide polymorphism in the FADS1\/FADS2 gene is associated with plasma lipid profiles in two genetically similar Asian ethnic groups with distinctive differences in lifestyle","volume":"127","author":"Nakayama","year":"2010","journal-title":"Hum. Genet."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib82","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib83","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/adc.2010.192401","article-title":"Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial","volume":"96","author":"Nobili","year":"2011","journal-title":"Arch. Dis. Child."},{"issue":"11","key":"10.1016\/j.mam.2018.03.001_bib84","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.numecd.2012.10.010","article-title":"Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutrition, metabolism, and cardiovascular diseases","volume":"23","author":"Nobili","year":"2013","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088005","article-title":"Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease","volume":"9","author":"Nobili","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib86","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/10408363.2015.1092106","article-title":"Omega-3 fatty acids: mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD","volume":"53","author":"Nobili","year":"2016","journal-title":"Crit. Rev. Clin. Lab Sci."},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib87","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clnu.2015.05.001","article-title":"Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial","volume":"35","author":"Nogueira","year":"2016","journal-title":"Clin. Nutr. (Edinb.)"},{"key":"10.1016\/j.mam.2018.03.001_bib88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1472-6793-8-21","article-title":"Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition","volume":"8","author":"Pachikian","year":"2008","journal-title":"BMC Physiol."},{"issue":"8","key":"10.1016\/j.mam.2018.03.001_bib89","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.numecd.2015.04.003","article-title":"A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease","volume":"25","author":"Pacifico","year":"2015","journal-title":"Nutr. Metabol. Cardiovasc. Dis. NMCD"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12944-016-0321-5","article-title":"Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease","volume":"15","author":"Paglialunga","year":"2016","journal-title":"Lipids Health Dis."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039362","article-title":"Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant","volume":"7","author":"Palmer","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib92","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J. Hepatol."},{"issue":"38","key":"10.1016\/j.mam.2018.03.001_bib93","doi-asserted-by":"crossref","first-page":"35931","DOI":"10.1074\/jbc.M306238200","article-title":"Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes","volume":"278","author":"Pawar","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib94","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.bbalip.2013.12.006","article-title":"Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function","volume":"1841","author":"Pingitore","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.mam.2018.03.001_bib95","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib96","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib97","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","article-title":"Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu","year":"2010","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.mam.2018.03.001_bib98","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib99","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1096\/fj.13-235614","article-title":"Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis","volume":"28","author":"Rius","year":"2014","journal-title":"FASEB J. Official publication of the Federation of American Societies for Experimental Biology"},{"issue":"12","key":"10.1016\/j.mam.2018.03.001_bib100","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib101","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1017\/S0007114508992564","article-title":"Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 ( FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes","volume":"101","author":"Rzehak","year":"2009","journal-title":"Br. J. Nutr."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib102","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ng.271","article-title":"Genome-wide association analysis of metabolic traits in a birth cohort from a founder population","volume":"41","author":"Sabatti","year":"2009","journal-title":"Nat. Genet."},{"issue":"18","key":"10.1016\/j.mam.2018.03.001_bib103","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib104","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mam.2018.03.001_bib105","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddl117","article-title":"Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids","volume":"15","author":"Schaeffer","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mam.2018.03.001_bib106","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-nutr-071812-161230","article-title":"Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease","volume":"33","author":"Scorletti","year":"2013","journal-title":"Annu. Rev. Nutr."},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib107","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s12020-011-9530-x","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments","volume":"40","author":"Scorletti","year":"2011","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib108","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib109","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cct.2014.02.002","article-title":"Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]","volume":"37","author":"Scorletti","year":"2014","journal-title":"Contemp. Clin. Trials"},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib110","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2015.07.036","article-title":"Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial","volume":"63","author":"Scorletti","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib111","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s10620-016-4143-0","article-title":"Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations","volume":"61","author":"Sherif","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"6","key":"10.1016\/j.mam.2018.03.001_bib112","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3181\/0711-MR-311","article-title":"The importance of the omega-6\/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases","volume":"233","author":"Simopoulos","year":"2008","journal-title":"Exp. Biol. Med."},{"issue":"12","key":"10.1016\/j.mam.2018.03.001_bib113","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.jnutbio.2011.11.009","article-title":"n-3 and n-6 polyunsaturated fatty acids differentially regulate adipose angiotensinogen and other inflammatory adipokines in part via NF-kappaB-dependent mechanisms","volume":"23","author":"Siriwardhana","year":"2012","journal-title":"J. Nutr. Biochem."},{"issue":"1\u20133","key":"10.1016\/j.mam.2018.03.001_bib114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000228995","article-title":"Review of fat and fatty acid requirements and criteria for developing dietary guidelines","volume":"55","author":"Smit","year":"2009","journal-title":"Ann. Nutr. Metabol."},{"issue":"23","key":"10.1016\/j.mam.2018.03.001_bib115","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.3748\/wjg.v20.i23.7339","article-title":"Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner?","volume":"20","author":"Sofi","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.mam.2018.03.001_bib116","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3109\/09637486.2010.487480","article-title":"Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study","volume":"61","author":"Sofi","year":"2010","journal-title":"Int. J. Food Sci. Nutr."},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib117","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","article-title":"Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease","volume":"61","author":"Softic","year":"2016","journal-title":"Dig. Dis. Sci."},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib118","first-page":"194","article-title":"Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease","volume":"40","author":"Spadaro","year":"2008","journal-title":"Digest. Liver Disease Official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib119","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.22940","article-title":"Independent effects of physical activity in patients with nonalcoholic fatty liver disease","volume":"50","author":"St George","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib120","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib121","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MCG.0b013e31815591aa","article-title":"Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis","volume":"42","author":"Tanaka","year":"2008","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000338","article-title":"Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study","volume":"5","author":"Tanaka","year":"2009","journal-title":"PLoS Genet."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib123","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2012-3093","article-title":"Clinical Review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications","volume":"98","author":"Targher","year":"2013","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5010003","article-title":"The effect of marine derived n-3 fatty acids on adipose tissue metabolism and function","volume":"5","author":"Todorcevic","year":"2015","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nut.2006.09.004","article-title":"Dietary habits and nutrient intake in non-alcoholic steatohepatitis","volume":"23","author":"Toshimitsu","year":"2007","journal-title":"Nutrition"},{"issue":"7","key":"10.1016\/j.mam.2018.03.001_bib126","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1194\/jlr.M050062","article-title":"Fatty acid elongase-5 (Elovl5) regulates hepatic triglyceride catabolism in obese C57BL\/6J mice","volume":"55","author":"Tripathy","year":"2014","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib127","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3945\/ajcn.2008.27107","article-title":"Does genetic variation in the Delta6-desaturase promoter modify the association between alpha-linolenic acid and the prevalence of metabolic syndrome?","volume":"89","author":"Truong","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"issue":"11","key":"10.1016\/j.mam.2018.03.001_bib128","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1017\/S0007114514002591","article-title":"Non-alcoholic fatty liver disease: need for a balanced nutritional source","volume":"112","author":"Veena","year":"2014","journal-title":"Br. J. Nutr."},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib129","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2310\/JIM.0b013e318177024d","article-title":"Effects of N-3 fatty acids on hepatic triglyceride content in humans. Journal of investigative medicine","volume":"56","author":"Vega","year":"2008","journal-title":"the official publication of the American Federation for Clinical Research"},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cgh.2008.12.015","article-title":"Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease","volume":"7","author":"Vuppalanchi","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol. The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"9","key":"10.1016\/j.mam.2018.03.001_bib131","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1194\/jlr.M600177-JLR200","article-title":"Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity","volume":"47","author":"Wang","year":"2006","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib132","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/hep.27373","article-title":"Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.mam.2018.03.001_bib133","article-title":"A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota","author":"Watson","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.mam.2018.03.001_bib134","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3945\/ajcn.2010.29457","volume":"92","author":"Welch","year":"2010","journal-title":"Am. J. Clin. Nutr."},{"issue":"2","key":"10.1016\/j.mam.2018.03.001_bib135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7861\/clinmedicine.7-2-119","article-title":"Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs","volume":"7","author":"Whalley","year":"2007","journal-title":"Clin. Med."},{"issue":"1","key":"10.1016\/j.mam.2018.03.001_bib136","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0021-9150(02)00307-6","article-title":"Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients","volume":"166","author":"Woodman","year":"2003","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.mam.2018.03.001_bib137","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1097-2765(00)80467-0","article-title":"Molecular recognition of fatty acids by peroxisome proliferator-activated receptors","volume":"3","author":"Xu","year":"1999","journal-title":"Mol. Cell"},{"issue":"27","key":"10.1016\/j.mam.2018.03.001_bib138","doi-asserted-by":"crossref","first-page":"18351","DOI":"10.1074\/jbc.M601277200","article-title":"Regulation of rat hepatic L-pyruvate kinase promoter composition and activity by glucose, n-3 polyunsaturated fatty acids, and peroxisome proliferator-activated receptor-alpha agonist","volume":"281","author":"Xu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mam.2018.03.001_bib139","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2862173","article-title":"The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background","volume":"2016","author":"Yu","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"issue":"4","key":"10.1016\/j.mam.2018.03.001_bib140","first-page":"1022","article-title":"The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: a systematic review and meta-analysis of RCTs","volume":"33","author":"Yu","year":"2017","journal-title":"Pakistan J. Med. Sci."},{"issue":"41","key":"10.1016\/j.mam.2018.03.001_bib141","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.3748\/wjg.14.6395","article-title":"Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia","volume":"14","author":"Zhu","year":"2008","journal-title":"World J. Gastroenterol."}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299718300190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299718300190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T18:11:26Z","timestamp":1758823886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299718300190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":141,"alternative-id":["S0098299718300190"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2018.03.001","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}